134 related articles for article (PubMed ID: 8669117)
1. Guidance of ganciclovir therapy with pp65 antigenemia in cytomegalovirus-free recipients of livers from seropositive donors.
Grossi P; Kusne S; Rinaldo C; St George K; Magnone M; Rakela J; Fung J; Starzl TE
Transplantation; 1996 Jun; 61(11):1659-60. PubMed ID: 8669117
[No Abstract] [Full Text] [Related]
2. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
Iberer F; Tscheliessnigg KH; Halwachs G; Auer T; Wasler A; Petutschnigg B; Müller H; Freigassner M; Allmayr T; Hipmair G
Wien Klin Wochenschr; 1995; 107(23):718-22. PubMed ID: 8560893
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of pp65 antigenemia and viremia in the follow-up of renal transplant recipients with cytomegalovirus disease treated with ganciclovir.
Reina J; Ballesteros F; Gasco J; Munar M; Mari M
Diagn Microbiol Infect Dis; 2000 Jun; 37(2):83-6. PubMed ID: 10863101
[TBL] [Abstract][Full Text] [Related]
4. Preemptive therapy for the prevention of cytomegalovirus disease following heart transplantation directed by PP65 antigenemia.
Villa M; Lage E; Ballesteros S; Cañas E; Sánchez M; Ordóñez A; Borrego JM; Hinojosa R; Cisneros JM
Transplant Proc; 2003 Mar; 35(2):732-4. PubMed ID: 12644115
[No Abstract] [Full Text] [Related]
5. A universal preemptive therapy for cytomegalovirus infections in children after live-donor liver transplantation.
Saitoh A; Sakamoto S; Fukuda A; Shigeta T; Kakiuchi T; Kamiyama S; Katsuta T; Shoji K; Ogimi C; Kasahara M
Transplantation; 2011 Oct; 92(8):930-5. PubMed ID: 21941226
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
7. Serum polymerase chain reaction for cytomegalovirus DNA for monitoring ganciclovir treatment in AIDS patients.
Marenzi R; Cinque P; Ceresa D; Racca S; Lillo F; Lazzarin A
Scand J Infect Dis; 1996; 28(4):347-51. PubMed ID: 8893396
[TBL] [Abstract][Full Text] [Related]
8. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay.
Lo CY; Ho KN; Yuen KY; Lui SL; Li FK; Chan TM; Lo WK; Cheng IK
Clin Transplant; 1997 Aug; 11(4):286-93. PubMed ID: 9267717
[TBL] [Abstract][Full Text] [Related]
9. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.
Solano C; Muñoz I; Gutiérrez A; Farga A; Prósper F; García-Conde J; Navarro D; Gimeno C
J Clin Microbiol; 2001 Nov; 39(11):3938-41. PubMed ID: 11682510
[TBL] [Abstract][Full Text] [Related]
10. Comparison of plasma polymerase chain reaction and pp65-antigenemia assay in the quantification of cytomegalovirus in liver and kidney transplant patients.
Piiparinen H; Höckerstedt K; Grönhagen-Riska C; Lappalainen M; Suni J; Lautenschlager I
J Clin Virol; 2001 Aug; 22(1):111-6. PubMed ID: 11418358
[TBL] [Abstract][Full Text] [Related]
11. Comparison of antigenemia assay and semiquantitative polymerase chain reaction test for monitoring active cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
Pajand O; Ziyaeyan M; Mousavi S; Fatolahzadeh B; Hojabri Z; Bahador A; Abdossamadi Z
Exp Clin Transplant; 2008 Jun; 6(2):149-54. PubMed ID: 18816243
[TBL] [Abstract][Full Text] [Related]
12. Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients. Longitudinal follow-up of CMV pp65 antigenemia assay.
Yang CW; Kim YO; Kim YS; Kim SY; Moon IS; Ahn HJ; Koh YB; Bang BK
Am J Nephrol; 1998; 18(5):373-8. PubMed ID: 9730559
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus reactivation and preemptive therapy after liver transplant.
Davoudi S; Kasraianfard A; Ahmadinejad Z; Najafi A; Salimi J; Makarem J; Sohrabpour AA; Jafarian A
Exp Clin Transplant; 2014 Mar; 12 Suppl 1():72-5. PubMed ID: 24635797
[TBL] [Abstract][Full Text] [Related]
14. In vitro model for the study of the dissociation of increasing antigenemia and decreasing DNAemia and viremia during treatment of human cytomegalovirus infection with ganciclovir in transplant recipients.
Gerna G; Sarasini A; Lilleri D; Percivalle E; Torsellini M; Baldanti F; Revello MG
J Infect Dis; 2003 Dec; 188(11):1639-47. PubMed ID: 14639533
[TBL] [Abstract][Full Text] [Related]
15. Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation.
Rayes N; Seehofer D; Schmidt CA; Oettle H; Müller AR; Steinmüller T; Settmacher U; Bechstein WO; Neuhaus P
Transplantation; 2001 Sep; 72(5):881-5. PubMed ID: 11571454
[TBL] [Abstract][Full Text] [Related]
16. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts.
Singh N; Wannstedt C; Keyes L; Mayher D; Tickerhoof L; Akoad M; Wagener MM; Cacciarelli TV
Liver Transpl; 2008 Feb; 14(2):240-4. PubMed ID: 18236404
[TBL] [Abstract][Full Text] [Related]
17. Clinical correlates of pp65 antigenemia monitoring in the first months of post kidney transplant in patients undergoing universal prophylaxis or preemptive therapy.
Carvalho FR; Cosendey RI; Souza CF; Medeiros T; Menezes PA; Silva AA; Almeida JR; Lugon JR
Braz J Infect Dis; 2017; 21(1):51-56. PubMed ID: 27888673
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus infection after liver transplantation using different prophylaxes.
Kornberg A; Grube T; Hommann M; Schotte U; Scheele J
Transplant Proc; 2001; 33(7-8):3624-5. PubMed ID: 11750539
[No Abstract] [Full Text] [Related]
19. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
Shah T; Lai WK; Mutimer D
Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy: a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients.
Kusne S; Grossi P; Irish W; St George K; Rinaldo C; Rakela J; Fung J
Transplantation; 1999 Oct; 68(8):1125-31. PubMed ID: 10551640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
